Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
Customer-centric product presentations for monoclonal antibodies
B Bittner - AAPS open, 2023 - Springer
Delivering customer-centric product presentations for biotherapeutics, such as monoclonal
antibodies (mAbs), represents a long-standing and paramount area of engagement for …
antibodies (mAbs), represents a long-standing and paramount area of engagement for …
Cost-analysis of subcutaneous vs intravenous administration of natalizumab based on patient care pathway in multiple sclerosis in Spain
AM Alonso Torres, AG Arevalo Bernabe… - PharmacoEconomics …, 2023 - Springer
Introduction A subcutaneous (SC) formulation of natalizumab has been recently authorised
for multiple sclerosis patients. This study aimed to assess the implications of the new SC …
for multiple sclerosis patients. This study aimed to assess the implications of the new SC …
Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
B Barrera, H Simpson, E Engebretson… - Annals of Clinical …, 2023 - Wiley Online Library
Objective This study aimed to evaluate safety (infusion‐related reactions [IRRs]) and patient
satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for …
satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for …
Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 …
Background In the context of the COVID-19 pandemic, French health authorities allowed the
home administration of natalizumab by a healthcare-at-home service. We evaluated the …
home administration of natalizumab by a healthcare-at-home service. We evaluated the …